Biotech Stocks Facing FDA Decision In June 2020

The FDA has been focusing mainly on COVID-19-related review since March. But that said, the regulatory decision on drugs proposed for rare tumors and life-threatening diseases has not been deferred. Now, let's take a look at the biotech stocks awaiting a regulatory decision in the month of June.

from RTT - Biotech https://ift.tt/2TDtTIZ
via IFTTT